Obermatt
See Similar Stocks →

Rezolute

NAQ:RZLT · US76200L3096
BiotechnologySmall

360° View

53
Price/Sales5
Price/Earnings69
Price/Book19
Dividend Yield1
Revenue Growth—
Profit Growth29
Capital Growth14
TSR 52w37
Leverage91
Liquidity67
Refinancing34
Combined41
Analyst Opinions40
Pro Holdings73
Opinion Changes50
Market Pulse81

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Employees58
Websiterezolutebio.com
ISINUS76200L3096
Last UpdateApr 2, 2026
Index & Theme
Chronic DiseasesGeneticsEndocrinologyOncologyGenetic DisorderBiotechnologyDiabetesTherapeutics

Description

Rezolute, Inc. (Rezolute), a late-stage rare disease company, focuses on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Summary of Clinical Assets Ersodetug The company’s lead clinical asset, ers…

Analysis

Rezolute's 360° View rank of 53 places it above its peer average — better than 53% of its true peers.

It's lagging on growth (15) and on the expensive side (39). On safety it is very well financed (78), and the market shows favorable sentiment (73). Taken together, its Combined rank of 41 reads as below its peer average.

360° rank · history

1007550250
53
2026

All-time high

63

Mar 2026

All-time low

53

Jun 2026

Average rank

58

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
5
—
—
—
Price/Earnings
69
—
—
—
Price/Book
19
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
39
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Rezolute with its peers
Embecta
NSQ:EMBC
55
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →
Mirum Pharmaceuticals
NMQ:MIRM
40
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Xeris Pharmaceuticals
NSQ:XERS
70
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Rhythm Pharmaceuticals
NMQ:RYTM
31
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Krystal Biotech
NSQ:KRYS
96
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →